Search
Showing results for "1"
Research
A psychometric examination of a modified eight-item version of the children's eating disorder examinationFurthermore, previous studies suggest that scores obtained from a simplified 8-item version of the ChEDE may be more reliable and useful for research...
Research
The gap in life expectancy from preventable physical illness in psychiatric patients in Western AustraliaDespite knowledge about excess mortality in people with mental illness, the gap in their life expectancy compared with the general population has widened...
Research Project Coordinator, Health Promotion & Education Research
Venue Information Accommodation Options Contact us THE UNIVERSITY CLUB OF WESTERN AUSTRALIA Hackett Entrance #1, Hackett Drive, Crawley, Western
News & Events
The Kids Research Institute Australia welcomes world-leading new laws for vapesThe Kids Research Institute Australia welcomes the Federal Government's stringent vaping reforms that took effect on 1 July 2024.
News & Events
Walkers unite for diabetesA record Perth crowd turned out for JDRF’s One Walk to raise much-needed funds for Type 1 Diabetes (T1D) research last month.
Research
Start Stronger, Live Longer Resource Manual for Aboriginal Health WorkersThis resource kit for Aboriginal health workers is an exciting milestone in the Rio Tinto Aboriginal Health partnership with The Kids Research Institute Australia
Research
A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCCEsophageal squamous cell carcinoma (ESCC) is a prevalent malignant tumor of the digestive tract with a low 5-year survival rate due to the lack of effective treatment methods. Although therapeutic monoclonal antibodies (mAbs) now play an important role in cancer therapy, effective targeted mAbs are still lacking for ESCC.
Research
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscapeRespiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly active.